Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Expands Worldwide Microchannel Patent Protection to South Korea
Korean Patent Includes Microfluidic Channel for Capturing Circulating Tumor Cells
View HTML
Toggle Summary Biocept Appoints Experienced Physician as Medical Director
Veena Singh, MD, FCAP, FACMG Brings Years of Medical Experience to Biocept Team
View HTML
Toggle Summary Biocept Reports Third Quarter 2014 Financial Results
SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30,
View HTML
Toggle Summary Biocept Launches Lung Cancer Offering
Blood-Based Liquid Biopsy Testing Launched for NSCLC Indications
View HTML
Toggle Summary Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for
View HTML
Toggle Summary Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel , Oct. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd.
View HTML
Toggle Summary Biocept Expands Collaboration With MD Anderson Cancer Center
Biocept's OncoCEE(TM) Platform Enhances Ovarian Cancer Research
View HTML
Toggle Summary Biocept to Present at the 13th Annual BIO Investor Forum
SAN DIEGO , Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall , Biocept President and CEO, is scheduled to
View HTML
Toggle Summary Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells
Patent Approval Further Strengthens Biocept's IP Position in Personalized Cancer Treatment in East-Asia
View HTML
Toggle Summary Biocept to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a
View HTML